chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A flu shot 6 years ago gave me ITP and almost killed me; almost killed; Initial information received on 01-Jan-2022 regarding an unsolicited valid Social Media serious case received from a consumer/non-hcp.  This case involves an unknown age and unknown gender patient who experienced a flu shot 6 years ago gave me itp and almost killed me and almost killed while receiving vaccine Influenza Vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a  dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site.  On an unknown date the patient developed a serious event a flu shot 6 years ago gave me  and almost killed me (immune thrombocytopenia) (unknown latency) and non-serious event almost killed (unevaluable event) (unknown latency) following the administration of Influenza Vaccine.    Action taken : not applicable.  Corrective treatment: No corrective reported for the events.  Event outcome : Unknown for both the events.  Seriousness criteria : This event(immune thrombocytopenia) was assessed as medically significant.; Sender's Comments: Sanofi company comment dated 06-Jan-2022. This case involves an unknown gender patient who experienced a flu shot 6 years ago gave me and almost killed me while receiving vaccine Influenza Vaccine. Based on the limited information provided regarding this case, causal role of the company suspect product cannot be excluded. Case will be re-evaluated post further update on the patient's underlying disease conditions, past medical and drug history, concurrent illnesses, and concomitant medications.
Red and inflammed cellulitis, 4 days post vax. Treated with ice, 600mg ibuprofen, Benadryl 25mg 1 q6h X 4 days.
covid 19; flu like symptoms; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (covid 19) and INFLUENZA LIKE ILLNESS (flu like symptoms) in a 67-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 055F22B) for COVID-19 prophylaxis.     Question:Was there parental vaccine exposure?Answer:No.  Previously administered products included for Product used for unknown indication: Pfizer (Dose 2) and Pfizer (Dose 1). Past adverse reactions to the above products included No adverse event with Pfizer and Pfizer.    On 03-Dec-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 03-Dec-2022, the patient experienced COVID-19 (covid 19) and INFLUENZA LIKE ILLNESS (flu like symptoms). The patient was treated with PARACETAMOL (TYLENOL) ongoing since an unknown date for Fever, at an unspecified dose and frequency. At the time of the report, COVID-19 (covid 19) and INFLUENZA LIKE ILLNESS (flu like symptoms) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Dec-2022, SARS-CoV-2 test: Positive.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Patient had flu like symptoms including fever, headache, coughing, body aches, and chills. Patient had been taking over the counter Coricidin HBP liquid.
Starting day after administration, she had excruciating pain inside her upper arm and numbness inside her forearm. She went to Doctor and started on Gabapentin 300mg every 6 hours as needed Monday 9/21/15.
Bilateral ear pain/ache; This is a spontaneous report from a non-contactable nurse (patient). A 39-year-old female patient (not pregnant) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. No other vaccine in four weeks. No COVID prior vaccination. No COVID tested post vaccination. The patient experienced bilateral ear pain/ache on 04Feb2021 20:00 with outcome of unknown. No treatment received for the event.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
9/19/13 Approx 9:30 a little itching at site, none since 9/19/13 10 PM - legs hurting terrible, 12MN-7AM hurting middle of lower back downward, legs, lower back, hips. Terrible pain. Could not move. Fever 100.5. Took 2 ES Tylenol-fever broke. 9/20/13 Feels really beat 8:30 AM-going home to rest-may see doctor. Had red, puffy area between L thumb and forefinger. No sign of a bite. No problem at site of injection.
pt became tachycardic reported to be 150bpm and diaphoretic. when pt called the clinic her syopmtoms had already resolved. see note in chart
Body feeling unusually cold , chills and shaking . Lasted overnight after vacinc=ation
Information has been received from a nurse practitioner concerning a 60 year old female with preexisting allergies, birth defects, and medical conditions to sulfonamide allergy, allergic reaction to antibiotics such as Keflex and Terramycin, hypertension, asthma and high cholesterol who on 17-OCT-2007 was vaccinated in the right deltoid with a dose of zoster vaccine live (Oka/Merck) (lot number: 658084/08880). There was no concomitant medication. There was no illness at time of vaccination. There was no adverse events following prior vaccination. There were no relevant diagnostic test and laboratory data. On 19-OCT-2007, the patient experienced circular erythematous induration with vesicular lesions in the center 232 mm in size with mild pink peri-induration, warmth with mild tenderness. Additional information has been requested.
A week after that vaccine at the site it was very sore and raised and red. It got bigger as the week went on. I contact my doctor that Thursday. She prescribed an antibiotic and a steroid cream and advised to use it until it was gone. I used all the cream and antibiotic. It did itch and hurt really pain. It was also hot to the touch. It went away.
I received the Pfizer Bivalent COVID-19 booster on 11/5/2022. On 12/4/2022, I experienced a slight sore throat late in the evening. On 12/5/2022, I woke up with sinus congestion and slight sore throat; it felt like a cold. I did a home antigen test, and the result was negative. On 12/6/2022, I continued to feel like I had a cold. I tested again and got another negative result. On 12/7/2022, I still felt like I had a bad cold, but I did not test that day. I still had a scratchy, sore throat and sinus congestion. I took my temperature each day, and I had no fever. On 12/8/2022, I felt worse. I had a fever of either 100 or 101. I tested again and got a positive result. I contacted my doctor, and she prescribed me PAXLOVID. I took my first and second doses that day. On 12/9/2022, I still had a fever, but the positive line on the test I took that day was a little fainter. On 12/10/2022, I tested negative and had no fever. On 12/11/2022, I again had no fever and tested negative. The medicine worked really well and really fast. I have not had any residual symptoms ever since.
I had the Moderna Booster and the next day I had flue like symptoms.  After taking a long nap I felt better and went to the grocery store.  While in the check out line I became faint and I passed out. The EMT's were called and I was taken to the ER by ambulance.  I had a similar reaction to my second shot in May, 2021, but that time I was at home so I was able to get down on the floor and crawl to a bed when I became faint.
"Patient did not feel as if he had received full dose as the vaccine was running down his arm/ the nurse administering the dose stated their was minimal leakage; This spontaneous case was reported by a nurse and describes the occurrence of DEVICE CONNECTION ISSUE ("Patient did not feel as if he had received full dose as the vaccine was running down his arm/ the nurse administering the dose stated their was minimal leakage) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027C21A and 036B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Sep-2021, the patient experienced DEVICE CONNECTION ISSUE ("Patient did not feel as if he had received full dose as the vaccine was running down his arm/ the nurse administering the dose stated their was minimal leakage). On 28-Sep-2021, DEVICE CONNECTION ISSUE ("Patient did not feel as if he had received full dose as the vaccine was running down his arm/ the nurse administering the dose stated their was minimal leakage) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided. Treatment information was not provided.
This spontaneous report has been received from a physician via a company representative, referring to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On an unspecified and separate dates, the patient was vaccinated with two doses of M-M-R II (strength, frequency, route, lot number and expiration date were not provided). Concomitant therapies were not provided. On an unknown date, after receiving both doses of the vaccine, the patient had a M-M-R II titer drawn which resulted negative (measles antibody negative, mumps antibody negative and rubella antibody negative). The outcome of rubella antibody negative, mumps antibody negative and measles antibody negative were unknown and the relatedness between the events and the suspect therapy was not reported. Additional information has been requested.
This case was reported by a healthcare professional and described the occurrence of asthmatic attack in a 49-year-old female subject who was vaccinated with FLULAVAL (GlaxoSmithKline). Concurrent medical conditions included asthma. On 7 October 2008 at 17:30 the subject received a dose of FLULAVAL at 0.5 ml in the left arm. Immediately after vaccination with FLULAVAL, the subject developed redness and swelling and five minutes later, hyperventilation. It became difficult for her to breath and an asthmatic attack was reported along with anxiety. The subject was treated with Epi pen. Her oxygen level and pulse were normal in the office. The paramedics were called and the subject was transported to the emergency department where she was evaluated and released. This case was assessed as medically serious by GSK. At the time of reporting the events were resolved. The reporter felt that the subject experienced an anxiety attack. Events of redness, swelling, hyperventilation and asthma attack were considered by the reporter, probably related to treatment with FLULAVAL.
Pt was given 2 vaccinations Td and MMR on 7/22/03. On 7/23/03 pt complained of right antecubital rash, red and itching. On 7/24/03 rash with swelling noted. Pt took Benadryl pills on 7/25/03 and symptoms decreased.
61year old was inadvertently given Fluzone HD with no reported adverse event; Initial information received on 20-Jan-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 61 years old of unknown gender patient who was inadvertently given fluzone hd with no reported adverse event ,while receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a  dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE( lot number not reported) at a unknown dose via unknown route in unknown administration site a prophylactic vaccination.  On an unknown date, the patient developed a non-serious event " 61year old was inadvertently given fluzone hd with no reported adverse event" (off label use) (unknown latency) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  It was reported" We had a 61 year old patient who was inadvertently given the Fluzone HD (65+ years old) product. I am wondering if there is any information from on the safety of this, or any precautions or steps we should take/offer to the patient. Let me know if you have any resources to assist us."  Action taken with QUADRIVALENT INFLUENZA VACCINE (FLUZONE HIGH-DOSE QUADRIVALENT) was not applicable.  It was not reported if the patient received a corrective treatment for the event (61year old was inadvertently given Fluzone HD with no reported adverse event).  At time of reporting, the outcome was Unknown for the event 61year old was inadvertently given fluzone hd with no reported adverse event.
Fever, started to have chills, kidney pain, dry heaves, fever, bodyaches, stomachache and lasted for 3 days. Today 3/1/2021 still c/o on Injection site pain, left arm weakness, feeling of mushy/atrophy, tingling, numbness Narrative:
Significant local reaction, swelling 4CM and tenderness of entire l upper arm, Fever 103 > 48 hours, Headache, vomiting, local plus Arthus type reaction improving at 72 hours.
This 18 month old male subject was enrolled in an open-label study for prophylaxis treatment of hepatitis A. On 02/28/2005, he received the 4th dose of combined diptheria, tetanus, acellular pertussis vaccine and Aventis Pasteur's haemophilus influenza type B vaccine. On 03/30/2005, he received the 1st dose of hepatitis A vaccine. On 05/24/2005, 95 days after the 4th dose of Infanrix, 85 days after the 4th dose of ActHIB, 55 days after the 1st dose of Mavrix, this 18 month old subject was observed to experience delayed expressive language abilities. On 10/26/2005, the child was evaluated with a cognitive delay of 11 months of age, receptive delay at 10 months level and expressive delay at 16 months level. The event was unresolved at time of reporting. After tests results, it was decided to withdraw the child from the study. The investigator considered that there was a reasonable possibility that the delayed expressive language abilities may have been caused by Infanrix, hemophilus influenza tetanus toxoid conjunate vaccine and hepatitis A vaccine. Further informations are awaited.
No adverse events or outcome, just that the vaccine was administered after the 30 days of received by our clinic.
Information has been received from a physician concerning a 6 month old male who was vaccinated PO with a second 2.0 mL dose of Rotateq.  In March 2007, after received the vaccine, the patient experienced persistent vomiting and diarrhea.  The patient was hospitalized for 24 hours.  No further information was provided.  Unspecified medical attention was sought.  The outcome was reported as recovered on 20-MAR-2007.  There was no product quality complaint.  Follow-up information from the reporting physician indicated that the patient was 2 months of age and received all the routine 2 month immunizations.  The patient was not hospitalized.  Lot numbers or additional patient information were unavailable since the physician did not remember the patient.  Additional follow-up information from the physician indicated that the patient was a 22 week old male with gastroesophageal reflux disease who on 02-MAR-2007, was vaccinated with his second dose of Rotateq.  There was no illness at the time of vaccination.  Concomitant vaccinations administered on that same day included the second dose of PedvaxHIB (OMPC) (MSD) (lot# 653770/0407F) in the right thigh, the second dose of DAPTACEL (lot# AC14B0400) in the left thigh, the second dose of IPOL (Vero) (lot# Z0421) in the left thigh, and the second dose of PREVNAR (lot# B08649H) in the left thigh.  Other concomitant drug therapy included AXID.  In March 2007 after vaccination on unspecified date and patient experienced dehydration characterized by fever, vomiting and diarrhea (previously reported).  The patient sought unspecified medical attention and was subsequently hospitalized.  Lab diagnostic studies included all normal results for abdominal ultrasound, abdominal X-ray, blood culture and urine culture.  On 15-MAR-2007 the patient recovered.  Additional information has been requested.
Patient was administered with vaccines that had undergone temperature excursion; Patient was administered with vaccines that had undergone temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Patient was administered with vaccines that had undergone temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient was administered with vaccines that had undergone temperature excursion) in a 37-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 059H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Jan-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patient was administered with vaccines that had undergone temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patient was administered with vaccines that had undergone temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Patient was administered with vaccines that had undergone temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient was administered with vaccines that had undergone temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported. No treatment medications was reported.  The vial was thawed on 28-Jan-2022. The vials had Maximum or minimum temperatures reached, as applicable (specify temp is in C or F). On 28-Jan-2022 temp range: positive 34.7F to positive 41.2F; on 30-Jan-2022 temp range: positive 34.7F to positive 41.2F which occurred approximately for 48 hours; on 31Jan2022 temp range: positive 34.7F to positive 41.2F for 12 hours and on 04-Feb-2022 temp range: positive 35.2F to positive 41.7F for 12 hours.   This case was linked to MOD-2022-539812 (Patient Link).
Received TWINRIX, TDP, flu, pneumonia vaccine. KEFLEX.
PATIENT BROUGHT PRESCIPTIONS TO PHARMACY FROM FAMILY PHYSICIAN FOR NAPROSYN & HYDROCODONE/APAP 5/500MG TO TREAT LEFT SHOULDER PAIN/NERVE DAMAGE ON 11/5/08
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality. The reporter is the patient.  A 37-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 15Mar2021 as dose 1,single (Lot number: EN6208), in left arm, on 05Apr2021 as dose 2, single (Lot number: ER8737), in left arm and on 15Oct2021 as dose 3 (booster) single (Lot number: KH8027) at the age of 36 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Severe asthma" (unspecified if ongoing); "chronic pneumonia" (unspecified if ongoing). Concomitant medication(s) included: SPIROLACTONE. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID rebound after taking paxlovid. Started paxlovid same day as positive covid test. Completed 5 day tx; Positive, notes: 7 days after final dosage, had return/new COVID symptoms, tested positive. Had little to no symptoms during first quarantine. Therapeutic measures were taken as a result of vaccination failure, covid-19.
10 1/2 x 13cm edematous, red & warm to touch area rt upper arm noted @ site of DTP inj;mom states pt c/o soreness & pain of rt arm 11DEC96;advised to take child to MD;
11/25/2022 in the morning I woke with cold symptoms. 11/28 tested with a rapid COVID-19 test, positive. Saw doctor at the pharmacy who proscribed lactoferrin and a Z-PAK. Mostly felt fatigue, joints in my fingers ached, but cold symptoms lasted a week. The symptoms gradually diminished.
I initially got sick within 24 hours of vaccine. I didn't go to the hospital and was out of work for 4 days. In September 2021 had an ER visit Hospital for blood pressure. It has been highly uncontrollable since vaccine. On October 9, 2021, I went to ER again at Hospital stated I had a stroke was hospitalized for 4 days been on medical leave since. I'm currently doing physical therapy for left side of my body, speech, and brain therapy.
Vaccinated at 240PM. Symptoms at 6PM. Red rash 1 inch x 2 inches, very hot, headache, nausea. Put ice on rash, her MD had her take TYLENOL and BENADRYL.
COVID 19; COVID 19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 31-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 07Oct2022 as dose 6 (booster), single (Lot number: GJ2524) at the age of 31 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 27May2022 as dose 5 (booster), single (Lot number: FM9992), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "Obesity" (unspecified if ongoing); "Sciatica" (unspecified if ongoing); "Eczema" (unspecified if ongoing); "PCOS" (unspecified if ongoing); "Chronic Sinusitis" (unspecified if ongoing); "Hidradenitis suppurativa" (unspecified if ongoing); "known allergies: Nickel" (unspecified if ongoing); "known allergies: Cobalt" (unspecified if ongoing); "known allergies: Penicillin" (unspecified if ongoing). Concomitant medication(s) included: KYLEENA; TRIAMCINOLONE; XYZAL. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19". Therapeutic measures were taken as a result of drug ineffective, covid-19.
In health dept. on 02/19/16. Received MCV and Tdap vaccine at approx. 11:30 am. Mom presents today, states child started w/fever 02/19/16 between 5-6 pm. Was in ER on Saturday 02/20/16. Shows us papers with diagnosis of fever and viral syndrome. Symptoms included fever, h/a, chills, body aches. Was released home same day and has follow up appt. with MD.
Patient states on 2/27/13 that she developed a rash on her (L) arm at the injection site, and (R) side of abdomen. Pt did not seek or receive treatment.
Headaches, weakness in muscles, shooting and dull pains all over, weakness in legs when trying to stand, charlie horses, red blood counts are high, tingling sensations
felt her throat tightening up; This is a spontaneous report from a contactable consumer (patient). A 65-years-old female patient received BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number and Expiration date was not reported), via an unspecified route of administration on 12Feb2021 as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported.  Patient stated that she received the first dose of the Pfizer COVID-19 vaccine 2 hours ago on 12Feb2021. Patient stayed for 15 minutes and when she got in the car to go home, she felt her throat tightening up and wanted to know if this was a common side effect. Patient wanted to know if she can take Benadryl. The outcome of the event was unknown.  Information on the Lot/Batch number has been requested. Follow-up attempts are completed. No further information is expected.